A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 588 participants.
Also called NCT04795531
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 588 participants
- Sponsor
- Registry
-
NCT04795531 -
2020-000472-37
-
- Other papers using this trial's data
- Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Brazil, Canada, China, Czechia, Denmark, France, Mexico, Puerto Rico, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT04795531. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-24 (actual); primary completion 2022-06-23 (actual). Results posted on 2024-12-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
- Acronym
- ONWARDS 3
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin icodec
- Intervention (Drug)
- Placebo insulin icodec
- Intervention (Drug)
- Insulin degludec
- Intervention (Drug)
- Placebo insulin degludec
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04795531- Content hash
8d920934e43dda8a4f7857de9ca6ebb643b1bccaf98c8b78d97f90aca27ce8ea